4kv1 › Citations

Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA.

Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J, Nair S, Chen LF
Oncogene 33 2395-404 (2014)
Cited: 154 times
EuropePMC logo PMID: 23686307

Abstract

Acetylation of the RelA subunit of NF-κB at lysine-310 regulates the transcriptional activation of NF-κB target genes and contributes to maintaining constitutively active NF-κB in tumors. Bromodomain-containing factor Brd4 has been shown to bind to acetylated lysine-310 (AcLys310) and to regulate the transcriptional activity of NF-κB, but the role of this binding in maintaining constitutively active NF-κB in tumors remains elusive. In this study, we demonstrate the structural basis for the binding of bromodomains (BDs) of bromodomain-containing protein 4 (Brd4) to AcLys310 and identify the BD inhibitor JQ1 as an effective small molecule to block this interaction. JQ1 suppresses TNF-α-mediated NF-κB activation and NF-κB-dependent target gene expression. In addition, JQ1 inhibits the proliferation and transformation potential of A549 lung cancer cells and suppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice. Furthermore, we demonstrate that depletion of Brd4 or treatment of cells with JQ1 induces the ubiquitination and degradation of the constitutively active nuclear form of RelA. Our results identify a novel function of Brd4 in maintaining the persistently active form of NF-κB found in tumors, and they suggest that interference with the interaction between acetylated RelA and Brd4 could be a potential therapeutic approach for the treatment of NF-κB-driven cancer.

Articles - 4kv1 mentioned but not cited (6)

  1. BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R. Cancer Discov 8 458-477 (2018)
  2. Molecular Mechanism Underlying Effects of Wumeiwan on Steroid-Dependent Asthma: A Network Pharmacology, Molecular Docking, and Experimental Verification Study. Lyu M, Wang Y, Chen Q, Qin J, Hou D, Huang S, Shao D, Gong X, Huang G, Zhang S, Zhang Z, Cui H. Drug Des Devel Ther 16 909-929 (2022)
  3. Network Pharmacology-Based Investigation on Therapeutic Mechanisms of the Angelica dahurica Radix and Ligusticum chuanxiong Rhizoma Herb Pair for Anti-Migraine Effect. Thanh CD, Men CV, Kim HM, Kang JS. Plants (Basel) 11 2196 (2022)
  4. Qing-Yi Decoction in the Treatment of Acute Pancreatitis: An Integrated Approach Based on Chemical Profile, Network Pharmacology, Molecular Docking and Experimental Evaluation. Wei TF, Zhao L, Huang P, Hu FL, Jiao JY, Xiang KL, Wang ZZ, Qu JL, Shang D. Front Pharmacol 12 590994 (2021)
  5. Tuo-Min-Ding-Chuan Decoction Alleviates Airway Inflammations in the Allergic Asthmatic Mice Model by Regulating TLR4-NLRP3 Pathway-Mediated Pyroptosis: A Network Pharmacology and Experimental Verification Study. Lyu M, Qin J, Huang S, Shao D, Huang G, Yang F, Gong X, Zhang S, Zhang Z, Wang J, Cui H. Drug Des Devel Ther 17 1613-1630 (2023)
  6. [Therapeutic mechanism of emodin for treatment of rheumatoid arthritis: a network pharmacology-based analysis]. Cao C, Zeng L, Rong X. Nan Fang Yi Ke Da Xue Xue Bao 42 913-921 (2022)


Reviews citing this publication (51)

  1. Getting up to speed with transcription elongation by RNA polymerase II. Jonkers I, Lis JT. Nat. Rev. Mol. Cell Biol. 16 167-177 (2015)
  2. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Shi J, Vakoc CR. Mol. Cell 54 728-736 (2014)
  3. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Fu LL, Tian M, Li X, Li JJ, Huang J, Ouyang L, Zhang Y, Liu B. Oncotarget 6 5501-5516 (2015)
  4. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Fujisawa T, Filippakopoulos P. Nat. Rev. Mol. Cell Biol. 18 246-262 (2017)
  5. Targeting BET bromodomains for cancer treatment. Jung M, Gelato KA, Fernández-Montalván A, Siegel S, Haendler B. Epigenomics 7 487-501 (2015)
  6. KATs in cancer: functions and therapies. Farria A, Li W, Dent SY. Oncogene 34 4901-4913 (2015)
  7. Bromodomain inhibitors and cancer therapy: From structures to applications. Pérez-Salvia M, Esteller M. Epigenetics 12 323-339 (2017)
  8. Targeting BET bromodomain proteins in solid tumors. Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. Oncotarget 7 53997-54009 (2016)
  9. Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Chen R, Yik JH, Lew QJ, Chao SH. Biomed Res Int 2014 232870 (2014)
  10. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Reinisch A, Chan SM, Thomas D, Majeti R. Semin. Hematol. 52 150-164 (2015)
  11. A chemical probe toolbox for dissecting the cancer epigenome. Shortt J, Ott CJ, Johnstone RW, Bradner JE. Nat. Rev. Cancer 17 160-183 (2017)
  12. Association of chromosome 19 to lung cancer genotypes and phenotypes. Wang X, Zhang Y, Nilsson CL, Berven FS, Andrén PE, Carlsohn E, Horvatovich P, Malm J, Fuentes M, Fuentes M, Végvári Á, Welinder C, Fehniger TE, Rezeli M, Edula G, Hober S, Nishimura T, Marko-Varga G. Cancer Metastasis Rev. 34 217-226 (2015)
  13. Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseases. Klein K. RMD Open 4 e000744 (2018)
  14. Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. Chueh AC, Tse JW, Tögel L, Mariadason JM. Antioxid. Redox Signal. 23 66-84 (2015)
  15. Constitutive NF-κB activation in AML: Causes and treatment strategies. Bosman MC, Schuringa JJ, Vellenga E. Crit. Rev. Oncol. Hematol. 98 35-44 (2016)
  16. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Gallipoli P, Giotopoulos G, Huntly BJ. Ther Adv Hematol 6 103-119 (2015)
  17. Targeting Cancer Cells with BET Bromodomain Inhibitors. Xu Y, Vakoc CR. Cold Spring Harb Perspect Med 7 (2017)
  18. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Brasier AR, Zhou J. Drug Discov Today 25 126-132 (2020)
  19. Osteosarcoma mechanobiology and therapeutic targets. Shoaib Z, Fan TM, Irudayaraj JMK. Br J Pharmacol 179 201-217 (2022)
  20. Chemical probes targeting epigenetic proteins: Applications beyond oncology. Ackloo S, Brown PJ, Müller S. Epigenetics 12 378-400 (2017)
  21. Epigenetic modulation in cancer immunotherapy. Gallagher SJ, Shklovskaya E, Hersey P. Curr Opin Pharmacol 35 48-56 (2017)
  22. The role of enhancer RNAs in epigenetic regulation of gene expression. Rahnamoun H, Orozco P, Lauberth SM. Transcription 11 19-25 (2020)
  23. BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer. Hajmirza A, Emadali A, Gauthier A, Casasnovas O, Gressin R, Callanan MB. Biomedicines 6 (2018)
  24. BRD4 and Cancer: going beyond transcriptional regulation. Donati B, Lorenzini E, Ciarrocchi A. Mol. Cancer 17 164 (2018)
  25. Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling. Kadiyala V, Smith CL. Mol. Endocrinol. 28 607-621 (2014)
  26. BET Proteins: An Approach to Future Therapies in Transplantation. Suarez-Alvarez B, Rodriguez RM, Ruiz-Ortega M, Lopez-Larrea C. Am. J. Transplant. 17 2254-2262 (2017)
  27. Inflammatory Immune-Associated eRNA: Mechanisms, Functions and Therapeutic Prospects. Wan L, Li W, Meng Y, Hou Y, Chen M, Xu B. Front Immunol 13 849451 (2022)
  28. RSV Reprograms the CDK9•BRD4 Chromatin Remodeling Complex to Couple Innate Inflammation to Airway Remodeling. Brasier AR. Viruses 12 (2020)
  29. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, Lou G, Yang C. Signal Transduct Target Ther 8 420 (2023)
  30. Chemical Protein Degradation Approach and its Application to Epigenetic Targets. Itoh Y. Chem Rec 18 1681-1700 (2018)
  31. Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease. Martinez-Moreno JM, Fontecha-Barriuso M, Martin-Sanchez D, Guerrero-Mauvecin J, Goma-Garces E, Fernandez-Fernandez B, Carriazo S, Sanchez-Niño MD, Ramos AM, Ruiz-Ortega M, Ortiz A, Sanz AB. Int J Mol Sci 21 (2020)
  32. NF-κB: A Druggable Target in Acute Myeloid Leukemia. Di Francesco B, Verzella D, Capece D, Vecchiotti D, Di Vito Nolfi M, Flati I, Cornice J, Di Padova M, Angelucci A, Alesse E, Zazzeroni F. Cancers (Basel) 14 3557 (2022)
  33. Phase separation drives the formation of biomolecular condensates in the immune system. Wen Y, Ma J. Front Immunol 13 986589 (2022)
  34. Protein phase separation: A novel therapy for cancer? Wang W, Chen Y, Xu A, Cai M, Cao J, Zhu H, Yang B, Shao X, Ying M, He Q. Br J Pharmacol 177 5008-5030 (2020)
  35. Recent progress and structural analyses of domain-selective BET inhibitors. Divakaran A, Harki DA, Pomerantz WCK. Med Res Rev 43 972-1018 (2023)
  36. Relevance of BET Family Proteins in SARS-CoV-2 Infection. Lara-Ureña N, García-Domínguez M. Biomolecules 11 1126 (2021)
  37. Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases. Morgado-Pascual JL, Rayego-Mateos S, Tejedor L, Suarez-Alvarez B, Ruiz-Ortega M. Front Pharmacol 10 1315 (2019)
  38. DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters? Ordoñez R, Martínez-Calle N, Agirre X, Prosper F. Cancers (Basel) 11 (2019)
  39. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Feng L, Wang G, Chen Y, He G, Liu B, Liu J, Chiang CM, Ouyang L. Med Res Rev 42 710-743 (2022)
  40. Emerging roles of and therapeutic strategies targeting BRD4 in cancer. White ME, Fenger JM, Carson WE. Cell. Immunol. 337 48-53 (2019)
  41. Enhancer RNA (eRNA) in Human Diseases. Wang Y, Zhang C, Wang Y, Liu X, Zhang Z. Int J Mol Sci 23 11582 (2022)
  42. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors. Liang Y, Wang L, Ma P, Ju D, Zhao M, Shi Y. Front Immunol 14 1308264 (2023)
  43. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Biomolecules 10 (2020)
  44. Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology. Morgado-Pascual JL, Marchant V, Rodrigues-Diez R, Dolade N, Suarez-Alvarez B, Kerr B, Valdivielso JM, Ruiz-Ortega M, Rayego-Mateos S. Mediators Inflamm. 2018 2931049 (2018)
  45. Nitric Oxide Antagonism to Anti-Glioblastoma Photodynamic Therapy: Mitigation by Inhibitors of Nitric Oxide Generation. Fahey JM, Girotti AW. Cancers (Basel) 11 (2019)
  46. Photodynamic Therapy as an Oxidative Anti-Tumor Modality: Negative Effects of Nitric Oxide on Treatment Efficacy. Girotti AW, Fahey JM, Korbelik M. Pharmaceutics 13 593 (2021)
  47. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. Vlahopoulos S, Adamaki M, Khoury N, Zoumpourlis V, Boldogh I. Pharmacol. Ther. 194 59-72 (2019)
  48. Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials. Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Front Pharmacol 11 621093 (2020)
  49. Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery. van der Noord VE, van de Water B, Le Dévédec SE. Cancers (Basel) 14 4353 (2022)
  50. The BET family in immunity and disease. Wang N, Wu R, Tang D, Kang R. Signal Transduct Target Ther 6 23 (2021)
  51. The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Verzella D, Cornice J, Arboretto P, Vecchiotti D, Di Vito Nolfi M, Capece D, Zazzeroni F, Franzoso G. Biomedicines 10 2233 (2022)

Articles citing this publication (97)

  1. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C. PLoS Pathog. 11 e1005063 (2015)
  2. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Lamoureux F, Baud'huin M, Rodriguez Calleja L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE, Heymann D, Ory B. Nat Commun 5 3511 (2014)
  3. Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, Taipaleenmäki H, Ben-Batalla I, Scheller M, Loges S, Knapp S, Hesse E, Chiang CM, Grundhoff A, Johnsen SA. Cell Rep 8 460-469 (2014)
  4. Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension. Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, Chabot S, Ruffenach G, Henry S, Breuils-Bonnet S, Tremblay È, Nadeau V, Lambert C, Paradis R, Provencher S, Bonnet S. Circ. Res. 117 525-535 (2015)
  5. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. Jung M, Philpott M, Müller S, Schulze J, Badock V, Eberspächer U, Moosmayer D, Bader B, Schmees N, Fernández-Montalván A, Haendler B. J. Biol. Chem. 289 9304-9319 (2014)
  6. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, Jin L, Pupo G, Cullinane C, McArthur GA, Tummino PJ, Rizos H, Hersey P. Pigment Cell Melanoma Res 27 1126-1137 (2014)
  7. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Blood 126 1565-1574 (2015)
  8. Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells. Fu W, Farache J, Clardy SM, Hattori K, Mander P, Lee K, Rioja I, Weissleder R, Prinjha RK, Benoist C, Mathis D. Elife 3 e04631 (2014)
  9. Biased multicomponent reactions to develop novel bromodomain inhibitors. McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE. J. Med. Chem. 57 9019-9027 (2014)
  10. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes. Xiao Y, Liang L, Huang M, Qiu Q, Zeng S, Shi M, Zou Y, Ye Y, Yang X, Xu H. Rheumatology (Oxford) 55 173-184 (2016)
  11. High level of BRD4 promotes non-small cell lung cancer progression. Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu JJ, Ding JY. Oncotarget 7 9491-9500 (2016)
  12. The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ. Mol. Cancer Ther. 15 1018-1028 (2016)
  13. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling. Wu X, Qi J, Bradner JE, Xiao G, Chen LF. J. Biol. Chem. 288 36094-36105 (2013)
  14. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Wong C, Laddha SV, Tang L, Vosburgh E, Levine AJ, Normant E, Sandy P, Harris CR, Chan CS, Xu EY. Cell Death Dis 5 e1450 (2014)
  15. BET Inhibition Attenuates Helicobacter pylori-Induced Inflammatory Response by Suppressing Inflammatory Gene Transcription and Enhancer Activation. Chen J, Wang Z, Hu X, Chen R, Romero-Gallo J, Peek RM, Chen LF. J. Immunol. 196 4132-4142 (2016)
  16. BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells. Muralidharan SV, Bhadury J, Nilsson LM, Green LC, McLure KG, Nilsson JA. Oncogene 35 4689-4697 (2016)
  17. BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. Sun Y, Wang Y, Toubai T, Oravecz-Wilson K, Liu C, Mathewson N, Wu J, Rossi C, Cummings E, Wu D, Wang S, Reddy P. Blood 125 2724-2728 (2015)
  18. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN. Leukemia 32 343-352 (2018)
  19. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. Zhang P, Dong Z, Cai J, Zhang C, Shen Z, Ke A, Gao D, Fan J, Shi G. Int J Immunopathol Pharmacol 28 36-44 (2015)
  20. BRD4 mediates NF-κB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation. Tian B, Zhao Y, Sun H, Zhang Y, Yang J, Brasier AR. Am. J. Physiol. Lung Cell Mol. Physiol. 311 L1183-L1201 (2016)
  21. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, Wu S, Yang H, Wykosky J, Frazer KA, Verkhusha VV, Isaguliants MG, Weiss WA, Gahman TC, Shiau AK, Chen CC, Mischel PS, Cavenee WK, Furnari FB. Genes Dev. 31 1212-1227 (2017)
  22. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer. Hong SH, Eun JW, Choi SK, Shen Q, Choi WS, Han JW, Nam SW, You JS. Oncotarget 7 32628-32640 (2016)
  23. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. Suarez-Alvarez B, Morgado-Pascual JL, Rayego-Mateos S, Rodriguez RM, Rodrigues-Diez R, Cannata-Ortiz P, Sanz AB, Egido J, Tharaux PL, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M. J. Am. Soc. Nephrol. 28 504-519 (2017)
  24. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision. Chiang CM. Chem. Biol. 21 804-806 (2014)
  25. LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer. Zhu Z, Song J, Guo Y, Huang Z, Chen X, Dang X, Huang Y, Wang Y, Ou W, Yang Y, Yu W, Liu CY, Cui L. Oncogene 39 4666-4680 (2020)
  26. The m6A methyltransferase METTL3 cooperates with demethylase ALKBH5 to regulate osteogenic differentiation through NF-κB signaling. Yu J, Shen L, Liu Y, Ming H, Zhu X, Chu M, Lin J. Mol Cell Biochem 463 203-210 (2020)
  27. The suppression of bromodomain and extra-terminal domain inhibits vascular inflammation by blocking NF-κB and MAPK activation. Huang M, Zeng S, Zou Y, Shi M, Qiu Q, Xiao Y, Chen G, Yang X, Liang L, Xu H. Br. J. Pharmacol. 174 101-115 (2017)
  28. Brd4 modulates the innate immune response through Mnk2-eIF4E pathway-dependent translational control of IκBα. Bao Y, Wu X, Chen J, Hu X, Zeng F, Cheng J, Jin H, Lin X, Chen LF. Proc. Natl. Acad. Sci. U.S.A. 114 E3993-E4001 (2017)
  29. Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. Mol. Pharm. 13 683-688 (2016)
  30. IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks. Serrels B, McGivern N, Canel M, Byron A, Johnson SC, McSorley HJ, Quinn N, Taggart D, Von Kreigsheim A, Anderton SM, Serrels A, Frame MC, Frame MC. Sci Signal 10 (2017)
  31. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains. Karim RM, Chan A, Zhu JY, Schönbrunn E. J Med Chem 63 3227-3237 (2020)
  32. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. Wasiak S, Dzobo KE, Rakai BD, Kaiser Y, Versloot M, Bahjat M, Stotz SC, Fu L, Sweeney M, Johansson JO, Wong NCW, Stroes ESG, Kroon J, Kulikowski E. Clin Epigenetics 12 166 (2020)
  33. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. Leukemia 35 2621-2634 (2021)
  34. Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208). Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Calosing C, Jahagirdar R, Johansson J, Sweeney M, Wong NC, Kulikowski E. J Cardiovasc Transl Res 10 337-347 (2017)
  35. Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4. Hu X, Dong SH, Chen J, Zhou XZ, Chen R, Nair S, Lu KP, Chen LF. Oncogene 36 5177-5188 (2017)
  36. Segmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase A. Williams FP, Milbradt AG, Embrey KJ, Bobby R. PLoS ONE 11 e0154607 (2016)
  37. BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF-κB activation. Gao F, Yang Y, Wang Z, Gao X, Zheng B. Cell. Immunol. 294 1-8 (2015)
  38. Bromodomain-containing Protein 4 Activates Voltage-gated Sodium Channel 1.7 Transcription in Dorsal Root Ganglia Neurons to Mediate Thermal Hyperalgesia in Rats. Hsieh MC, Ho YC, Lai CY, Wang HH, Lee AS, Cheng JK, Chau YP, Peng HY. Anesthesiology 127 862-877 (2017)
  39. Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation. Kim DE, Procopio MG, Ghosh S, Jo SH, Goruppi S, Magliozzi F, Bordignon P, Neel V, Angelino P, Dotto GP. J. Exp. Med. 214 2349-2368 (2017)
  40. Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma. Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Cancer Res 79 2415-2425 (2019)
  41. The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC. Wollebo HS, Bellizzi A, Cossari DH, Salkind J, Safak M, White MK. J. Neurovirol. 22 615-625 (2016)
  42. BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis. Dong X, Hu X, Chen J, Hu D, Chen LF. Cell Death Dis 9 203 (2018)
  43. Epigenetic dysregulation of interleukin 8 (CXCL8) hypersecretion in cystic fibrosis airway epithelial cells. Poghosyan A, Patel JK, Clifford RL, Knox AJ. Biochem. Biophys. Res. Commun. 476 431-437 (2016)
  44. Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. Sanz-Álvarez M, Cristóbal I, Luque M, Santos A, Zazo S, Madoz-Gúrpide J, Caramés C, Chiang CM, García-Foncillas J, Eroles P, Albanell J, Rojo F. Cancers (Basel) 13 1246 (2021)
  45. Quantifying the Selectivity of Protein-Protein and Small Molecule Interactions with Fluorinated Tandem Bromodomain Reader Proteins. Kalra P, McGraw L, Kimbrough JR, Pandey AK, Solberg J, Cui H, Divakaran A, John K, Hawkinson JE, Pomerantz WCK. ACS Chem Biol 15 3038-3049 (2020)
  46. RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation. Rahnamoun H, Lee J, Sun Z, Lu H, Ramsey KM, Komives EA, Lauberth SM. Nat. Struct. Mol. Biol. 25 687-697 (2018)
  47. Upstream signaling events leading to elevated production of pro-survival nitric oxide in photodynamically-challenged glioblastoma cells. Fahey JM, Korytowski W, Girotti AW. Free Radic Biol Med 137 37-45 (2019)
  48. A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7). van Beijnum JR, Nowak-Sliwinska P, van Berkel M, Wong TJ, Griffioen AW. Angiogenesis 20 641-654 (2017)
  49. BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. Antolic A, Wakimoto H, Jiao Z, Gorham JM, DePalma SR, Lemieux ME, Conner DA, Lee DY, Qi J, Seidman JG, Bradner JE, Brown JD, Haldar SM, Seidman CE, Burke MA. JCI Insight 5 (2020)
  50. Bromodomain Containing Protein 4 (BRD4) Regulates Expression of its Interacting Coactivators in the Innate Response to Respiratory Syncytial Virus. Xu X, Mann M, Qiao D, Li Y, Zhou J, Brasier AR. Front Mol Biosci 8 728661 (2021)
  51. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays. Sun Z, Zhang H, Chen Z, Xie Y, Jiang H, Chen L, Ding H, Zhang Y, Jiang H, Zheng M, Luo C. Bioorg. Med. Chem. Lett. 27 2003-2009 (2017)
  52. Histone Adduction and Its Functional Impact on Epigenetics. Galligan JJ, Marnett LJ. Chem. Res. Toxicol. 30 376-387 (2017)
  53. Inhibition of BRD4 Reduces Neutrophil Activation and Adhesion to the Vascular Endothelium Following Ischemia Reperfusion Injury. Reid S, Fine N, Bhosle VK, Zhou J, John R, Glogauer M, Robinson LA, Scholey JW. Int J Mol Sci 21 E9620 (2020)
  54. Inhibition of BRD4 prevents proliferation and epithelial-mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis. Tan YF, Wang M, Chen ZY, Wang L, Liu XH. Cell Death Dis 11 239 (2020)
  55. Methods to detect NF-κB acetylation and methylation. Chen J, Chen LF. Methods Mol. Biol. 1280 395-409 (2015)
  56. Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1. Fahey JM, Stancill JS, Smith BC, Girotti AW. J. Biol. Chem. 293 5345-5359 (2018)
  57. Optimization of a "bump-and-hole" approach to allele-selective BET bromodomain inhibition. Runcie AC, Zengerle M, Chan KH, Testa A, van Beurden L, Baud MGJ, Epemolu O, Ellis LCJ, Read KD, Coulthard V, Brien A, Ciulli A. Chem Sci 9 2452-2468 (2018)
  58. Site-specific azide-acetyllysine photochemistry on epigenetic readers for interactome profiling. Sudhamalla B, Dey D, Breski M, Nguyen T, Islam K. Chem Sci 8 4250-4256 (2017)
  59. Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Liu M, Cao S, He L, Gao J, Arab JP, Cui H, Xuan W, Gao Y, Sehrawat TS, Hamdan FH, Ventura-Cots M, Argemi J, Pomerantz WCK, Johnsen SA, Lee JH, Gao F, Ordog T, Mathurin P, Revzin A, Bataller R, Yan H, Shah VH. Nat Commun 12 4560 (2021)
  60. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR. Oncogene 38 1717-1733 (2019)
  61. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. Lee M, Tayyari F, Pinnaduwage D, Bayani J, Bartlett JMS, Mulligan AM, Bull SB, Andrulis IL. BMC Cancer 18 750 (2018)
  62. BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells. Kapoor S, Damiani E, Wang S, Dharmanand R, Tripathi C, Tovar Perez JE, Dashwood WM, Rajendran P, Dashwood RH. Nutrients 14 4317 (2022)
  63. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Wu T, Wang G, Chen W, Zhu Z, Liu Y, Huang Z, Huang Y, Du P, Yang Y, Liu CY, Cui L. Cell Death Dis 9 315 (2018)
  64. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites. Olp MD, Sprague DJ, Goetz CJ, Kathman SG, Wynia-Smith SL, Shishodia S, Summers SB, Xu Z, Statsyuk AV, Smith BC. ACS Chem Biol 15 1036-1049 (2020)
  65. DNA methylation in genes of longevity-regulating pathways: association with obesity and metabolic complications. Salas-Pérez F, Ramos-Lopez O, Mansego ML, Milagro FI, Santos JL, Riezu-Boj JI, Martínez JA. Aging (Albany NY) 11 1874-1899 (2019)
  66. DUB3 Facilitates Growth and Inhibits Apoptosis Through Enhancing Expression of EZH2 in Oral Squamous Cell Carcinoma. Luo F, Zhou Z, Cai J, Du W. Onco Targets Ther 13 1447-1460 (2020)
  67. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Blood 135 1255-1269 (2020)
  68. Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats. Xiong C, Deng J, Wang X, Shao X, Zhou Q, Zou H, Zhuang S. Front Pharmacol 12 636154 (2021)
  69. Repeatedly next-generation sequencing during treatment follow-up of patients with small cell lung cancer. JiaXin Y, XiaoFeng C, PengFei C, Songchen Z, Ziling L. Medicine (Baltimore) 102 e34143 (2023)
  70. Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation. Tian B, Liu Z, Yang J, Sun H, Zhao Y, Wakamiya M, Chen H, Rytting E, Zhou J, Brasier AR. Cell Rep 23 1138-1151 (2018)
  71. Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells. Negri A, Marozzi M, Trisciuoglio D, Rotili D, Mai A, Rizzi F. J Enzyme Inhib Med Chem 38 2163242 (2023)
  72. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. Tarantelli C, Cannas E, Ekeh H, Moscatello C, Gaudio E, Cascione L, Napoli S, Rech C, Testa A, Maniaci C, Rinaldi A, Zucca E, Stathis A, Ciulli A, Bertoni F. Explor Target Antitumor Ther 2 586-601 (2021)
  73. N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells. Nord JA, Wynia-Smith SL, Gehant AL, Jones Lipinski RA, Naatz A, Rioja I, Prinjha RK, Corbett JA, Smith BC. Front Endocrinol (Lausanne) 13 923925 (2022)
  74. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB, Chen H. PLoS ONE 13 e0200826 (2018)
  75. BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC. Shi L, Xiong Y, Hu X, Wang Z, Xie C. Int J Med Sci 18 3090-3096 (2021)
  76. Characterization of molecular mechanisms driving Merkel cell polyomavirus oncogene transcription and tumorigenic potential. Yang JF, Liu W, You J. PLoS Pathog 19 e1011598 (2023)
  77. CircKCNQ5 controls proliferation, migration, invasion, apoptosis, and glycolysis of multiple myeloma cells by modulating miR-335-5p/BRD4 axis. Li Y, Wang L, Zhang N, Xu Y. Histol Histopathol 38 525-536 (2023)
  78. Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair. Huan S, Gui T, Xu Q, Zhuang S, Li Z, Shi Y, Lin J, Gong B, Miao G, Tam M, Zhang HT, Zha Z, Wu C. Cancer Manag Res 12 4429-4439 (2020)
  79. Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. Vann KR, Pal D, Smith AL, Sahar NE, Krishnaiah M, El-Gamal D, Kutateladze TG. Mol Biomed 3 2 (2022)
  80. Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1. Mumby S, Perros F, Grynblat J, Manaud G, Papi A, Casolari P, Caramori G, Humbert M, John Wort S, Adcock IM. Respir Res 24 193 (2023)
  81. Enhanced transcriptional heterogeneity mediated by NF-κB super-enhancers. Wibisana JN, Inaba T, Shinohara H, Yumoto N, Hayashi T, Umeda M, Ebisawa M, Nikaido I, Sako Y, Okada M. PLoS Genet 18 e1010235 (2022)
  82. Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease. Wasiak S, Gilham D, Daze E, Tsujikawa LM, Halliday C, Stotz SC, Rakai BD, Fu L, Jahagirdar R, Sweeney M, Johansson JO, Wong NCW, Kulikowski E. Cardiovasc Ther 2020 9397109 (2020)
  83. Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis. Tejedor-Santamaria L, Morgado-Pascual JL, Marquez-Exposito L, Suarez-Alvarez B, Rodrigues-Diez RR, Tejera-Muñoz A, Marchant V, Mezzano S, Lopez-Larrea C, Sola A, Fernandez-Juarez GM, Ortiz A, Rayego-Mateos S, Ruiz-Ortega M. Pharmaceuticals (Basel) 15 121 (2022)
  84. H. pylori infection confers resistance to apoptosis via Brd4-dependent BIRC3 eRNA synthesis. Chen Y, Sheppard D, Dong X, Hu X, Chen M, Chen R, Chakrabarti J, Zavros Y, Peek RM, Chen LF. Cell Death Dis 11 667 (2020)
  85. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Zhou Y, Jin X, Yu H, Qin G, Pan P, Zhao J, Chen T, Liang X, Sun Y, Wang B, Ren D, Zhu S, Wu H. Theranostics 12 2080-2094 (2022)
  86. Inhibition of BET Protein Function Suppressed the Overactivation of the Canonical NF-κB Signaling Pathway in 6-OHDA-Lesioned Rat Model of Levodopa-Induced Dyskinesia. Wan Y, Han L, Rong L, Yang S, Song L, Wu N, Liu Z, Gan J. Front Neurosci 16 896322 (2022)
  87. Inhibition of BRD4 attenuates cardiomyocyte apoptosis via NF-κB pathway in a rat model of myocardial infarction. Sun Y, Xie Y, Du L, Sun J, Liu Z. Cardiovasc Ther 36 (2018)
  88. MiR-101-containing extracellular vesicles bind to BRD4 and enhance proliferation and migration of trophoblasts in preeclampsia. Cui J, Chen X, Lin S, Li L, Fan J, Hou H, Li P. Stem Cell Res Ther 11 231 (2020)
  89. MiR-129-5p Inactivates NF-κB Pathway to Block Rheumatoid Arthritis Development via Targeting BRD4. Wu Z, Chen D. J Healthc Eng 2022 8330659 (2022)
  90. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. Divakaran A, Talluri SK, Ayoub AM, Mishra NK, Cui H, Widen JC, Berndt N, Zhu JY, Carlson AS, Topczewski JJ, Schonbrunn EK, Harki DA, Pomerantz WCK. J. Med. Chem. 61 9316-9334 (2018)
  91. Molecular Dynamics Simulations Combined with Markov Model to Explore the Effect of Allosteric Inhibitor Binding on Bromodomain-Containing Protein 4. Yang X, Gao Y, Cao F, Wang S. Int J Mol Sci 24 10831 (2023)
  92. RORα is crucial for attenuated inflammatory response to maintain intestinal homeostasis. Oh SK, Kim D, Kim K, Boo K, Yu YS, Kim IS, Jeon Y, Im SK, Lee SH, Lee JM, Ko Y, Lee H, Park D, Fang S, Baek SH. Proc. Natl. Acad. Sci. U.S.A. 116 21140-21149 (2019)
  93. TNFα-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity. Yang H, Zhao X, Liu J, Jin M, Liu X, Yan J, Yao X, Mao X, Li N, Liang B, Xie W, Zhang K, Zhao J, Liu L, Huang G. Oncogene 42 35-48 (2023)
  94. The Microtubule-Targeting Agent Pretubulysin Impairs the Inflammatory Response in Endothelial Cells by a JNK-Dependent Deregulation of the Histone Acetyltransferase Brd4. Primke TF, Ingelfinger R, Elewa MAF, Macinkovic I, Weigert A, Fabritius MP, Reichel CA, Ullrich A, Kazmaier U, Burgers LD, Fürst R. Cells 12 2112 (2023)
  95. Treating type-1 diabetes with an epigenetic drug. Kitagawa Y, Ohkura N. Elife 3 e05720 (2014)
  96. Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis. Morgado-Pascual JL, Suarez-Alvarez B, Marchant V, Basantes P, Tharaux PL, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M, Rayego-Mateos S. Int J Mol Sci 24 486 (2022)
  97. Uncovering the non-histone interactome of the BRPF1 bromodomain using site-specific azide-acetyllysine photochemistry. Barman S, Padhan J, Sudhamalla B. J Biol Chem 300 105551 (2023)


Quick links